Advice

Following a full submission

teriparatide (Forsteo®) is not recommended for use within NHS Scotland for the treatment of osteoporosis in men at increased risk of fracture.

Teriparatide was associated with a greater increase in lumbar spine bone mineral density than placebo.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

Download detailed advice94KB (PDF)

Download

Medicine details

Medicine name:
teriparatide (Forsteo)
SMC ID:
490/08
Indication:
For the treatment of osteoporosis in men at increased risk of fracture.
Pharmaceutical company
Eli Lilly and Company Ltd
BNF chapter
Endocrine system
Submission type
Full
Status
Not recommended
Date advice published:
11 August 2008